Source comparison
Thymosin Alpha-1 40s Age Specific Protocol | Real Peptides Comparison
Before implementing any thymosin alpha-1 40s age specific protocol, understanding the distinction between research-grade peptide sources and poorly characterized products matters for reproducibility and safety. Real Peptides synthesizes thymosin alpha-1 throug
This comparison does not assign a generated winner or score.
- Before implementing any thymosin alpha-1 40s age specific protocol, understanding the distinction between research-grade peptide sources and poorly characterized products matters for reproducibility and safety. Real Peptides synthesizes thymosin alpha-1 through solid-phase peptide synthesis with ≥98% purity verified by HPLC and mass spectrometry. Batch-to-batch consistency is critical when you're titrating dose based on immune response.
- Real Peptides Tα1
- HPLC + MS confirmed ≥98%
- 1.6–3.2 mg per injection
- Twice weekly
- Research-grade synthesis with disclosed amino acid sequencing. Appropriate for protocols requiring dose precision and immune marker tracking
- Generic compounded Tα1
- COA provided, method unspecified
- Functional for general use but lacks batch-level traceability. Acceptable if immune monitoring isn't part of protocol
- Over-the-counter 'thymic peptide complex'
- None disclosed
- Variable (often underdosed)
- Daily oral
- Oral bioavailability of intact Tα1 is effectively zero due to gastric degradation. These products do not deliver the active peptide
- Pharmaceutical-grade Tα1 (Zadaxin)
- Full GMP with FDA oversight
- 1.6 mg standard
- Gold standard for clinical trials but cost-prohibitive for most research applications outside institutional settings